title: [New targeted therapies in breast cancer].
abstract: Trastuzumab improves care of patients with HER2+ breast cancer and allows a major gain in terms of survival. T-DM1 and pertuzumab are two new treatments, which give very encouraging results in metastatic breast cancer. Their place in neo-adjuvant and adjuvant setting still remains to be defined. Bevacizumab have its place in metastatic breast cancer. In adjuvant setting, results are disappointing and in neo-adjuvant setting, we need more studies on subgroups, which can benefit more. Development of the PARP inhibitors was slowed down by recent negative results in metastatic breast cancer but studies continue with more targeted patient's. Finally, everolimus, inhibitor of mTOR, allows to by pass the hormono-resistance in metastatic phase. Its toxicity must be taken into account in particular in adjuvant setting.
authors.affiliation: Centre des maladies du sein, hôpital St-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: florencecoussy@hotmail.com.
authors.forename: F
authors.initials: F
authors.lastname: Coussy
authors.affiliation: Centre des maladies du sein, hôpital St-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot 7, 10, avenue de Verdun, 75010 Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Teixeira
authors.affiliation: Centre des maladies du sein, hôpital St-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Giacchetti
authors.affiliation: Centre des maladies du sein, hôpital St-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Cuvier
authors.affiliation: Centre des maladies du sein, hôpital St-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Hocini
authors.affiliation: Centre des maladies du sein, hôpital St-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot 7, 10, avenue de Verdun, 75010 Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Espié
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D000077341:Lapatinib; D008453:Maytansine / Q000031:analogs & derivatives / Q000627:therapeutic use; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011799:Quinazolines / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000037:antagonists & inhibitors; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D000068878:Trastuzumab / Q000627:therapeutic use
chemical_list: D000080044:Ado-Trastuzumab Emtansine; D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000077341:Lapatinib; D008453:Maytansine; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D058570:TOR Serine-Threonine Kinases; D000068878:Trastuzumab; C546842:MTOR protein, human; C485206:pertuzumab
keywords: Breast cancer; Cancer du sein; Survie; Survival; Targeted therapies; Thérapies ciblées